The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CGEM | -8.07% | N/A | N/A | -57% |
| S&P | +13.14% | +87.24% | +13.37% | +78% |
Cullinan Oncology, Inc. is a biopharmaceutical company engaged in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.08M | -3.9% |
| Market Cap | $350.31M | -63.9% |
| Market Cap / Employee | $3.16M | 0.0% |
| Employees | 111 | 30.6% |
| Net Income | -$50.61M | -24.8% |
| EBITDA | -$55.52M | -13.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $103.34M | 1.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $1.19M | -5.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -38.12% | -13.1% |
| Return On Invested Capital | -16.51% | -1.4% |
| Q4 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$36.63M | -102.0% |
| Operating Free Cash Flow | -$36.88M | -8.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.13 | 0.75 | 0.80 | 0.71 | -51.78% |
| Price to Tangible Book Value | 1.13 | 0.75 | 0.80 | 0.71 | -51.78% |
| Enterprise Value to EBITDA | -5.76 | -2.62 | -2.38 | -0.34 | -95.86% |
| Return on Equity | -32.1% | -36.6% | -36.0% | -40.2% | 53.49% |
| Total Debt | $2.15M | $1.84M | $1.52M | $1.19M | -51.43% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
